HHS drug pricing advisor dies

Daniel Best, a senior advisor to HHS Secretary Alex Azar, passed away, the agency announced Thursday. He worked with HHS on drug pricing reform.

"It is with tremendous sadness that I learned of the passing of our friend and colleague," Azar said in a statement. "I had the great privilege to know Dan Best for the past decade. He joined me here at HHS out of a desire to serve the American people by making healthcare more affordable. He brought his deep expertise and passion to this task with great humility and collegiality."

Best formerly worked as an executive with CVS Health. HHS did not specify a cause of death.

“What a loss to our country and to all of us personally who had the great privilege of working with Dan," CMS Administrator Seema Verma said. "We appreciate his dedication and commitment, and his warmth, sincerity, and generosity came through in everything he did."

President Trump, HHS and CMS recently announced their plan to lower drug prices by reforming Medicare Part B payments to reflect international prices. The model could be introduced in a proposed rule in 2019.

Best published a blog post about the new model on Oct. 30 on HHS’ website.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.